Biperiden

When ATH:
N04AA02

Characteristic.

The white crystalline powder, without smell, slightly soluble in water and alcohol.

Pharmacological action.
Antiparkinsonian.

Application.

Syndrome parkinsonizma, Parkinson's disease, extrapyramidal disorder, dyskinesias, akinezii, drug induced, incl. neuroleptics.

Contraindications.

Hypersensitivity, zakrыtougolynaya glaucoma, megacolon, obstruction of the digestive tract, integuments, prostatauxe, pregnancy, breast-feeding.

Pregnancy and breast-feeding.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

Side effects.

From the nervous system and sensory organs: fatigue, weakness, dizziness, drowsiness, alarm, confusion, euphoria, memory impairment, hallucinations, midriaz, ccomodation.

Cardio-vascular system and blood (hematopoiesis, hemostasis): tachycardia / bradycardia, low blood pressure.

From the digestive tract: dry mouth, dyspeptic disorders.

Other: allergic reactions, strangury, drug dependence.

Cooperation.

It enhances the effects of anticholinergics, antihistamines, antiparkinsonian and anticonvulsants, ters-metoclopramide. Incompatible with alcohol. Quinidine increases the impact holinoliticheskoe, levodopa is the risk of psoriasis.

Overdose.

Symptoms: expressed holinoliticheskie effects.

Treatment: symptomatic. Perhaps the use of cholinesterase inhibitors.

Dosing and Administration.

Inside, I / or / m. The dosage and frequency of administration are selected individually, depending on the indication and the patient's age.

Precautions.

Be wary appoint cerebrovascular (advanced age), patients with epilepsy (should consider the possibility of seizures). Stop treatment gradually (high probability of withdrawal). Patients, receiving the drug, It should refrain from activities potentially hazardous activities, requiring speed of mental and motor reactions.

Cooperation

Active substance	Description of interaction
Acrivastine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Amitriptyline	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Haloperidol	FMR: synergism. Enhances increased intraocular pressure, It increases the risk of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Difengidramin	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Imipramine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Quetiapine	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Clemastine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Klozapyn	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Clomipramine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Lithium carbonate	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Loratadine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Maprotilin	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Metoclopramide	FMR: antagonizm. Against the backdrop of weaker effect biperiden.
Oxybutynin	FMR: synergism. Increases (mutually) frequency and / or severity of anticholinergic side effects (dry mouth, constipation, drowsiness and others).
Olanzapine	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Perfenazyn	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Promethazine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; with a joint appointment caution (Perhaps the Central antiholinergicski syndrome — atropinopodobnaja intoxication).
Risperidone	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Tioridazin	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Trifluoperazine	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Fexofenadine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Quinidine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Chlorpromazine	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Chlorprothixene	FMR: synergism. Do effect; It increases the likelihood of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Cetirizine	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Ciprogeptadin	FMR: synergism. Strengthens (mutually) holinolitichesky effect; possible development of the central anticholinergic syndrome (atropinopodobnaya intoxication).
Ethanol	It enhances the effect deprimiriruyuschy; the period of treatment is necessary to eliminate the use of alcohol.